ABSTRACT. Cytokeratin 8 (CK8) and cytokeratin 19 (CK19) is a specific cytoskeletal component of simple epithelia, including bronchial epithelial cells. We hypothesized that CK8 or CK19 released from epithelial cells may bind to and cause damage to extracellular matrixes through binding of anti-CK8 or anti-CK19 autoantibodies. In the present study, bindings of recombinant human CK8 and CK19 to laminin (both derived from mouse sarcoma cells and human), collagen, gelatin, and fibronectin were evaluated by a modified enzyme-linked immunosorbent assay (ELISA). In addition, binding of CK19 to laminin was also confirmed by inhibition assay. As a result, CK19 strongly bound to mouse laminin as well as human laminin. Pretreatment with laminin significantly reduced the binding of CK19 to laminin. However, binding of recombinant CK19 to laminin was not demonstrated by Western immunoblot, suggesting that SDS treatment of laminin diminished the binding. These results suggest that released CK19 from epithelial cells may have played a role in the damage of basement membrane by accumulation of an immune complex composed by CK19 and anti-CK19 autoantibody.
Cytokeratins (Cks) are a multigene family of polypeptides which form the cytoskeleton of epithelial cells. On the basis of differences in molecular weight and pH, at least 20 different types of CKs have been identified. These are expressed in certain sets along various routes of epithelial differentiation in normal epithelium, tumor cells, and culture cells (Moll et al., 1982; Fuchs, 1988; Coulombe, 1993; Steinert, 1993) . Cytokeratin 8 (CK8) and cytokeratin 19 (CK19) are specific cytoskeletal structures of simple epithelia, including bronchial epithelial cells (Moll et al., 1982; Fuchs, 1988; Coulombe, 1993; Steinert, 1993) . Although the precise mechanism of their generation remains unknown, fragments of cytokeratin are soluble in serum and can be detected with the aid of monoclonal antibodies in patients with lung cancer (Pujol et al., 1993) . In addition, a CYFRA 21-1 assay has been developed. Combines 2 monoclonal antibodies directed specifically against the degradation product of CK19 (Pujol et al., 1993) . Clinical investigations have suggested that serum CYFRA 21-1 is one of the most important tumor markers in the follow-up of non-small cell lung cancer, especially squamous cell lung cancer (Pujol et al., 1993) . Furthermore, we have previously demonstrated that anti-CK8 and anti-CK19 autoantibodies are formed in patients with idiopathic pulmonary fibrosis (Dobashi et al., 1998; Fujita et al., 1999) .
In this study, we hypothesized that recombinant CK8 or recombinant CK19 may bind to extracellular matrixes and we demonstrate new evidence that recombinant CK19 has the ability to interact with the major basement membrane protein, laminin.
Materials and Methods
Binding of cytokeratin 19 to laminin, collagen, gelatin and fibronectin
Tests for binding of CK8 or CK19 to various extracellular matrixes were performed using modified enzyme-linked immunosorbent assays (ELISA). For binding assays, polystyrene microtiter plates (ELISA plates, Cooke Laboratory Products Div., Dynatech Laboratories Inc., Alexandria, VA, USA) were coated with various concentrations of mouse laminin (from basement membrane of Engelbreth-Holm-Swarm Mouse sarcoma, lot 79H4000, Sigma Chemical Co., St Louis, MO, USA), human laminin (derived from human placenta, purified by immunoaffinity from pepsinized placenta, lot 19H4052, Sigma Chemical Co.), collagen (Type I, derived from calf skin, lot 87H2303, Sigma Chemical Co.), gelatin (Bio-Rad Laboratories, Hercules, CA, USA), and fibronectin (derived from human plasma, lot 38683, CAPPEL TM Reseach Products, Durham, NC, USA). The purity of laminin was checked by Coomassie blue staining of a sodium dodecyl sulfate (SDS)-polyacrylamide gel.
After washing, commercially available recombinant human CK8 (Progen Biotechnik GMBH, lot 65138, Heidelberg, Germany) or CK19 (Progen Biotechnik GMBH, lot 503209, Heidelberg, Germany) was incubated in wells for 60 min. After washing the plate, bound CK8 or CK19 was incubated with mouse monoclonal anti-human CK8 (clone 18.7, Progen Biotechnik GMBH, Heidelberg, Germany, at 1:1000 dilution) or with mouse monoclonal anti-human CK19 (clone 19.2, Progen Biotechnik GMBH, Heidelberg, Germany, at 1:1000 dilution). After incubation and washing, the solid phase-bound mouse monoclonal anti-human CK8 or CK19 antibody was further incubated with peroxidaseconjugated goat anti-mouse IgG antibody (Sigma ImmunoChemicals, lot 38H4856, St Louis, MO, USA, diluted 1:1000) for 60 min. After further washes, TMB Peroxidase EIA Substrate Kit (BioRad Laboratories, Hercules, CA, USA) was used to measure the amount of solid phase-bound antibodies. All incubations were performed at room temperature. Data were expressed as mean±standard deviation from triplicate determinations.
Avidity of binding of cytokeratin 19 to extracellular matrix
The binding of CK19 to extracellular matrixes was further characterized by testing the capacity of the extracellular matrixes to inhibit binding of CK19 to laminin. For inhibition assays, the microtiter plate wells were coated with 0.5 mg/ml of laminin. Recombinant human CK19 was preincubated with several concen- trations of laminin, and the amount of cytokeratin 19 bound to the wells was detected with enzyme conjugated antibodies as described above. Data were expressed as mean±standard deviation from triplicate determinations, and results were given as a percentage of inhibition.
SDS-PAGE electrophoresis and Western blotting
SDS-polyacrylamide gel electrophoresis was performed according to Laemmli's method (Laemmli, 1970 ) with a slight modification. Commercially available laminin was mixed with SDS (2.0%) and heated (100°C, 5 min). The samples were then applied to a 10/20% SDS polyacrylamide gel, electrophoresed (60 mA, 120 min.), fixed in 50% methanol, 10% acetic acid, and stained with Coomassie Blue. Proteins were then electrophoretically transferred onto nitrocellulose membrane by the method described previously (Towbin et al., 1979) . Laminin transferred to nitrocellulose membrane was incubated with recombinant human CK19 (2 mg/ml) for 60 min. Recombinant human CK19 was then detected by immunoblotting using the mouse monoclonal anti-human CK19 (clone 19.2, at 1:1000 dilution) and peroxidase conjugated goat antimouse IgG antibody (Sigma ImmunoChemicals, lot 38H4856, St. Louis, MO, USA), and stained with 4CN PLUS for chromogenic detection of horse radish peroxidase (NEM TM Life Science Products, Boston, MA, USA). In addition, recombinant human CK19, recombinant human CK8, and albumin were transferred to nitrocellulose membrane and incubated with mouse laminin (2 mg/ ml) for 60 min. Mouse laminin was then detected by immunoblotting using rabbit anti-mouse laminin antibody (LSL Co., Ltd., Tokyo, Japan, lot 832011, at 1:100 dilution) and peroxidase conjugated goat anti-rabbit IgG antibody (Sigma ImmunoChemicals, lot 68H4875, St Louis, MO, USA), and stained with 4CN PLUS for chromogenic detection of horse radish peroxidase (NEM TM Life Science Products, Boston, MA, USA).
Results
Human recombinant CK19 bound dose dependently to mouse laminin (Fig. 1B) . In addition, human recombinant CK19 bound dose dependently to human laminin (Fig. 1D) . In contrast, cytokeratin 8 did not bind to mouse laminin or human laminin (Fig. 1A, 1C) . Human recombinant CK19 bound slightly to collagen (Fig. 2B) . In contrast, cytokeratin 8 did not bind to collagen (Fig. 2A) . Neither human recombinant CK19 or recombinant CK8 bound to gelatin (data not shown). Human recombinant CK19 bound slightly to fibronectin (Fig. 3B) . In contrast, CK8 did not bind to fibronectin (Fig. 3A) . The binding of CK19 to mouse laminin was inhibited by preincubation with mouse laminin (Fig. 4) . However, the binding of CK19 to mouse laminin was not inhibited by the preincubation with human albumin or human transferrin (data not shown). By Western immunoblot analysis, we could not demonstrate that recombinant human CK19 bound to mouse or human laminin transferred to nitrocellulose membrane (Fig. 5A) . However, we clearly demonstrated that mouse laminin bound to CK19 transferred to nitrocellulose membrane (Fig. 5B) .
Discussion
In our present study, we first demonstrated that recombinant CK19 bound to extracellular matrix, laminin.
Laminin, the major glycoprotein in all basement membranes, consists of the thin extracellular matrices that underlie epithelial cells and endothelial cells and surround nerve, muscle, and fat cells (Beck et al., 1990; Timpl et al., 1987) . Laminin consists of two different B chains (B1 and B2) of about the same size (230 and 220 kDa) and a larger A chain (400 kDa), which are assembled into a cross-shaped structure stabilized by disulfide bonds (Beck et al., 1990; Timpl et al., 1987) . This glycoprotein was first isolated from the Engelbreth-Holm-Swarm tumor because it can readily be extracted and purified in intact form under nonreducing and nondenaturing conditions. This laminin exhibits an overall identity of 74% in G2 to G5 regions with human laminin and 90% in other parts of the molecule (Beck et al., 1990) . Numerous studies have indicated that laminin has diverse biological activities which include stimulating adhesion, migration, growth, and differentiation of various cells Sasaki et al., 1988; Aumailley et al., 1987; Graf et al., 1987; Kubota et al., 1992) . It binds cells through cell surface receptors (integrins and nonintegrin proteins) and interacts with other components of basement membranes including collagen IV, heparan sulfate proteoglycan, and nidogen/ entactin (Mecham, 1991; Clement et al., 1990; Languino et al., 1989; Shimizu et al., 1990) .
In the present study, we first demonstrated the binding of recombinant CK19 to mouse laminin as well as human laminin. We previously demonstrated the formation anti-CK19 autoantibody in patients with idiopathic pulmonary fibrosis (Fujita et al., 1999) and autoimmune hepatitis (in preparation). It has been reported that CK19 fragment is released from epithelial cells by the digestion of protease (Nakamura et al., 1997) . Therefore, there is a possibility that this released CK19 fragment accumulates in the extracellular matrix, laminin. If CK19 or its fragments are released, it may accumulate in laminin, at which point the anti-CK19 autoantibody, which is formed in patients with certain diseases, may attack the basement membrane. Therefore, binding of CK19 to laminin suggests the possibility of damage to the basement membrane by the autoantibody against CK19 derived from epithelial cells. This evidence may be clinically important since anti-CK19 antibody can react with CK19 as well as the basement membrane through the binding of CK19 to laminin.
In the present study, we could not prove the binding of CK19 to mouse or human laminin transferred to the nitrocellulose membrane. It has been suggested that the recognition of laminin as the autoantigen in SLE patients depends on laminin conformation, which is related to the lack of reactivity observed by Western immunoblot in patients' sera (Garcia Lerma et al., 1995) . This is in agreement with previous observations in which the binding of H241, a monoclonal anti-DNA antibody with anti-laminin activity derived from an MRL-lpr/lpr mice, can be abolished with the exposure of laminin to sodium dodecyl sulfate, whereas a polyclonal anti-laminin antibody also reacts with denatured laminin (Sabbaga et al., 1989) .
In conclusion, our data demonstrate that CK19 specifically bound to laminin. These results suggest that released CK19 from epithelial cells may play a role in the damage of basement membrane by accumulation of the immune complex composed by CK19 and anti-CK19 autoantibody.
